ReviewAmerican journal of translational research2018
Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation.
Review in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Effect of the Consumption of Species from the Zingiberaceae or Berberidaceae Family on Glycemic Profile Parameters: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- A novel berberine derivative B12 exhibits superior anti-obesity effects via targeting brown and white adipocyte dynamics.International journal of obesity (2005) · 2026Article
- Metabolic and Anti-Inflammatory Effects of Berberine-Rationale for Its Therapeutic Potential in Polycystic Ovary Syndrome.International journal of molecular sciences · 2026Review
- Natural Products Targeting Angiogenesis and Tumor Microenvironment in Gastrointestinal Malignancies.Cells · 2026Review
- Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case-control study.Frontiers in endocrinology · 2026Article
- Long-term traditional Chinese medicine use and incidence of metabolic syndrome in schizophrenia: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence.European journal of medical research · 2025Review
- Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics.Journal of nanobiotechnology · 2025Review
- Review
- Nutritional valorization of Manila tamarind accessions through antioxidant analysis and UHPLC-Q-TOF-MS-based metabolomic profiling.Frontiers in nutrition · 2025Article
- Berberine improves cognitive impairment by alleviating brain atrophy and promoting white matter reorganization in diabetic db/db mice: a magnetic resonance imaging-based study.Metabolic brain disease · 2024Article
- Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers.Pharmaceutics · 2023Article
- Development of Gelled-Oil Nanoparticles for the Encapsulation and Release of Berberine.ACS omega · 2023Article
- Berberine-A Promising Therapeutic Approach to Polycystic Ovary Syndrome in Infertile/Pregnant Women.Life (Basel, Switzerland) · 2023Review
- Berberine suppressed sarcopenia insulin resistance through SIRT1-mediated mitophagy.Open life sciences · 2023Article
- Factors Associated with White Fat Browning: New Regulators of Lipid Metabolism.International journal of molecular sciences · 2022Review
- Dietary berberine alleviates high carbohydrate diet-induced intestinal damages and improves lipid metabolism in largemouth bass (Frontiers in nutrition · 2022Article
- Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus.Adipocyte · 2021Review
- Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction.International journal of molecular sciences · 2021Review
- Biological Activity of Berberine-A Summary Update.Toxins · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Berberine (BBR), an isoquinoline alkaloid that derived from the Chinese medicinal plant Coptis chinensis, has been identified with multiple pharmacological activities, including regulating glucose and cholesterol levels, anti-obesity effects and anti-diabetic effects. Due to its multiple activities, BBR and its metabolites have drawn great attention in biomedical research and clinical practices. After the recent re-discovery of brown adipose tissue (BAT) in adult humans, stimulating energy-dissipating via BAT activation and white-to-brown adipose tissue conversion have been regarded as potential therapeutic strategies for obesity and diabetes. Recent studies have demonstrated the activities of BBR in the activation of BAT and white-to-brown adipose tissue conversion, showing significant effectiveness in the treatment of diabetes. This review has summarized current studies that focused on the effect of BBR in the treatment of metabolic syndrome, especially in regulating BAT activities. Besides, the potential and molecular mechanisms of BBR in treating other risk factors of metabolic syndrome, including insulin resistance and dyslipidemia, are also reviewed, showing the great potential of BBR in treating the metabolic syndrome systematically.
Indexed as
Identifiers
30662589PMC6291723W2944054634What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.